• 한국콘텐츠학회논문지
• /
• 제9권2호
• /
• pp.432-438
• /
• 2009

본 연구에서는 마이크로 라만 스펙트럼을 이용한 급성 알코올성 간 손상과 만성 에탄올 간섬유증의 진단을 위해, 전처리 과정을 거친 스펙트럼으로부터 변별력 있는 피크를 추출하여 자동 분류기를 이용한 진단하는 방법을 살펴보았다. 전처리 단계에서는 기준선의 왜곡을 제거한 후 피크 보존에 유용한 Savitzky-Golay 필터를 이용하여 smoothing하였다. 전처리 후 급성 알코올성 간 손상과 만성 에탄올성 간섬유증을 구분할 수 있는 변별력 있는 스펙트럼 피크를 확인하고 이를 이용하여 MAP과 신경망으로 분류하였으며 실험 결과에 의하면 제안한 전처리 방법과 자동 분류기로 만성 에탄올성 간섬유증과 급성 알코올성 간 손상을 80% 이상 분류할 수 있었고, 이는 특징 벡터로 사용한 피크가 간 질병 진단에 사용될 수 있는 가능성을 보여준다고 할 수 있다.

• 한방비만학회지
• /
• 제22권2호
• /
• pp.158-166
• /
• 2022

Objectives: The purpose of this meta-analysis was to evaluate the effects of berberine on non-alcoholic fatty liver disease (NAFLD) through a systematic review and meta-analysis. Methods: We searched seven electronic databases for studies through October 2022. All randomized controlled trials (RTCs) of berberine were included. Data extraction and risk of bias assessments were performed by two independent reviewers. The RevMan 5.4.1 program was used for meta-analysis. Results: A total of 279 relevant studies were identified, and 6 eligible RCTs were included to study the efficacy berberine on NAFLD. The six selected trials are studies on the effect between berberine and conventional treatment combined treatment versus conventional treatment. Liver function tests, blood lipid levels, and blood glucose levels were assessed. Combination treatment with berberine, ursodeoxycholate acid, metformin, and monascus purpureus showed statistically significant improvements in liver function levels, blood lipid levels, and blood glucose levels compared to conventional treatment alone. However, there was no significant efficacy of berberine combination dietary, exercise than control group on NAFLD. The meta-analysis results of examining 4 RCTs comparing the therapeutic efficacy of berberine showed statistically significant improvement in the liver function test, blood lipids levels, blood glucose levels. Conclusions: This study suggests that berberine has positive efficacy on blood lipids, blood glucose liver function, fatty liver condition of NAFLD. However, the level of evidence is low because of small effect size,so further investigation is needed.

• Nutrition Research and Practice
• /
• 제12권2호
• /
• pp.110-117
• /
• 2018

BACKGROUND/OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and is closely associated with metabolic syndrome. In the present study, we observed the effect of ethanol extract of Allium fistulosum (EAF) on NAFLD and have suggested the possibility of using EAF as a natural product for application in the development of a treatment for NAFLD. MATERIALS/METHODS: The preventive effect on hepatic lipid accumulation was estimated by using an oleic acid (OA)-induced NAFLD model in vitro and a Western diet (high-fat high-sucrose; WD)-induced obese mouse model. Animals were divided into three groups (n = 7): normal diet group (ND), WD group, and WD plus 1% EAF group. RESULTS: EAF reduced OA-stimulated lipid accumulation in HepG2 cells in the absence of cellular cytotoxicity and significantly blocked transcriptional activation of sterol regulatory element-binding protein 1 and fatty acid synthase genes. Subsequently, we investigated these effects in vivo in mice fed either ND or WD in the presence or absence of EAF supplementation. In comparison to the ND controls, the WD-fed mice exhibited increases in body weight, liver weight, epididymal fat weight, and accumulation of fat in hepatocytes, and these effects were significantly attenuated by EAF supplementation. CONCLUSIONS: Allium fistulosum attenuates the development of NAFLD, and EAF elicits anti-lipogenic activity in liver. Therefore, EAF represents a promising candidate for use in the development of novel therapeutic drugs or drug combinations for the prevention and treatment of NAFLD.

• The Korean Journal of Physiology and Pharmacology
• /
• 제24권5호
• /
• pp.385-394
• /
• 2020

Eupatilin is known to possess anti-apoptotic, anti-oxidative, and anti-inflammatory properties. We report here that eupatilin has a protective effect on the ethanol-induced injury in rats. Sprague-Dawley rats were divided into 6 groups: control, vehicle, silymarin, eupatilin 10 mg/kg, eupatilin 30 mg/kg, and eupatilin 100 mg/kg. Plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were analyzed to determine the extent of liver damage. Total cholesterol (TC) and triglycerides (TG) were analyzed to determine the level of liver steatosis. Malondialdehyde level, superoxide dismutase (SOD) activity, and glutathione (GSH) level were analyzed to determine the extent of oxidative stress. Tumor necrosis factor (TNF)-α and interleukin (IL)-1β were quantified to verify the degree of inflammation. Based on our findings, chronic alcohol treatment significantly changed the serum indexes and liver indicators of the model rats, which were significantly improved by eupatilin treatment. Rats in the eupatilin-treatment group showed reduced levels of AST, ALT, TG, TC, TNF-α, and IL-1β, increased SOD activity and GSH levels, and improved overall physiology compared to the alcoholic liver disease model rats. H&E staining also verified the eupatilin-mediated improvement in liver injury. In conclusion, eupatilin inhibits alcohol-induced liver injury via its antioxidant and anti-inflammatory effects.

• 비만대사연구학술지
• /
• 제2권2호
• /
• pp.71-75
• /
• 2023

Obesity is closely related to chronic diseases and cancer. The present case report aims to discuss the anti-obesity treatment strategy and the evaluation of the clinical progress in a patient with obesity and concurrent fatty liver disease. Following five months of treatment with liraglutide and rosuvastatin, the patient had a weight reduction of 3 kg (4.7%), a decrease in fasting blood sugar by 42 mg/dl (26.6%), a decrease in low-density lipoprotein cholesterol by 82 mg/dl (60.2%), and decrease in alanine transaminase. This case report documented the treatment of a patient with common chronic diseases encountered in the outpatient setting. Based on the therapeutic effects documented in clinical and laboratory indices, the anti-obesity treatment plan significantly aided in managing chronic diseases.

• Journal of Dairy Science and Biotechnology
• /
• 제32권1호
• /
• pp.1-6
• /
• 2014

Probiotics have been extensively studied for their beneficial effects on human health. In particular, Lactobacillus and Bifidobacterium strains have gained considerable attention as major groups of probiotic bacteria that improve gastrointestinal health. However, emerging evidence suggests that probiotics offer benefits beyond those observed in the gut recent studies suggest that probiotics and/or their components exert favorable effects on alcoholic liver disease (ALD) pathogenesis such as decreasing intestinal permeability, inhibiting pathogenic bacteria growth, increasing the activity of alcohol metabolism enzymes, modulating the adaptive immune system, and suppressing fatty acid synthesis genes. In this review, we discuss the results of in vivo and in vitro studies that have examined the use of probiotics to prevent ALD, primarily focusing on those that explore the cellular and molecular mechanisms underlying the activities of promising probiotic strains. The evidence presented in this review could help in screening for probiotic strains that have protective effects in ALD patients and in further elucidating the mechanisms of their actions.

• 대한한의학회지
• /
• 제36권4호
• /
• pp.74-79
• /
• 2015

Objectives: Here we investigated the anti-lipogenic potential of kaurenoic acid (KA), a diterpene derived from Aralia continentalis, in a cellular model of non-alcoholic fatty liver disease. Methods: HepG2 cells were treated with palmitate for 24h to induce intracellular lipid accumulation. To assess the influence of KA on steatotic HepG2 cells, various concentration of KA was co-administered. After palmitate treatment, Intracellular triglyceride content was measured. Expression level of several lipogenic genes, sterol regulatory element-binding transcription factor-1c (SREBP-1c), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase-1 (SCD-1) were measured using Western-blot analyses or RT-PCR. Results: Palmitate markedly increased intracellular triglyceride level and expression of related lipogenic genes in HepG2 cells, and which was relieved by co-administered KA. Conclusions: It is conceivable that that KA may have a pharmacological potential to reduce lipid accumulation in non-alcoholic fatty liver disease.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제11권2호
• /
• pp.204-209
• /
• 2008

저자들은 뇌하수체저하증을 동반한 조기에 발병된 소아 비만 환자에서 비알코올성 지방간질환의 진행으로 인한 간경화를 경험하였기에 이를 보고하는 바이며, 향후 뇌하수체저하증이 동반된 비만 환자에서 비알코올성 지방간질환의 발생 및 진행에 대한 주의 깊은 관찰이 필요할 것으로 사료된다.

• 한국콘텐츠학회논문지
• /
• 제9권6호
• /
• pp.237-246
• /
• 2009

최근 성인 남성에서 비만 인구가 늘어나며, 심혈관질환을 야기하는 대사증후군 유병률이 증가하고 있고, 증상이 없지만 지방간으로 진단되는 환자가 늘고 있다. 본 연구는 알코올성 또는 비알코올성 지방간 질환과 대사증후군과의 관련성이 있는지 알아보고자 하였다. 799명의 남성을 대상으로 평소 음주량을 조사하였고, 초음파 검사를 통해 지방간 유무를 확인 한 결과 297명은 정상군이었고, 206명은 알코올성 지방간, 296명은 비알코올성 지방간이었다. IDF(international diabetes federation) 기준을 적용한 대사증후군과 구성요소들을 독립변수로, AFLD(alcoholic fatty liver disease) 및 NAFLD(nonalcoholic fatty liver disease)을 종속변수로 하여 로지스틱 회귀분석을 실시하였다. 정상군과 AFLD 또는 NAFLD에서 대사증후군의 분포는 각각 7.4%, 48.8%, 34.9%이었고, 대사증후군 구성요소 중 고혈압, 고혈당, 고중성지방, 비만은 AFLD 또는 NAFLD의 위험인자였고, AFLD에선 고중성지방과 복부비만이, NAFLD에서는 복부비만이 영향력이 가장 큰 것으로 나타났다. 또한 AFLD군의 경우 대사증후군과 비만, 저HDL-콜레스테롤의 이상범위에서 지방간 중증의 교차비가 높았고, NAFLD군에서는 대사증후군과 고중성지방군의 이상범위에서 지방간 중증의 교차비가 높았다. 결론적으로 AFLD 및 NAFLD는 대사증후군 구성요소 각각의 기준과 밀접한 관련성이 있었고, 지방간 관리를 위해 꾸준하고 포괄적인 접근이 필요하다.

• Biomolecules & Therapeutics
• /
• 제31권3호
• /
• pp.253-263
• /
• 2023

The biogenesis and biological roles of extracellular vesicles (EVs) in the progression of liver diseases have attracted considerable attention in recent years. EVs are membrane-bound nanosized vesicles found in different types of body fluids and contain various bioactive materials, including proteins, lipids, nucleic acids, and mitochondrial DNA. Based on their origin and biogenesis, EVs can be classified as apoptotic bodies, microvesicles, and exosomes. Among these, exosomes are the smallest EVs (30-150 nm in diameter), which play a significant role in cell-to-cell communication and epigenetic regulation. Moreover, exosomal content analysis can reveal the functional state of the parental cell. Therefore, exosomes can be applied to various purposes, including disease diagnosis and treatment, drug delivery, cell-free vaccines, and regenerative medicine. However, exosome-related research faces two major limitations: isolation of exosomes with high yield and purity and distinction of exosomes from other EVs (especially microvesicles). No standardized exosome isolation method has been established to date; however, various exosome isolation strategies have been proposed to investigate their biological roles. Exosome-mediated intercellular communications are known to be involved in alcoholic liver disease and nonalcoholic fatty liver disease development. Damaged hepatocytes or nonparenchymal cells release large numbers of exosomes that promote the progression of inflammation and fibrogenesis through interactions with neighboring cells. Exosomes are expected to provide insight on the progression of liver disease. Here, we review the biogenesis of exosomes, exosome isolation techniques, and biological roles of exosomes in alcoholic liver disease and nonalcoholic fatty liver disease.